{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T09:36:01Z","timestamp":1648978561340},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.eimc.2009.12.004","type":"journal-article","created":{"date-parts":[[2010,2,10]],"date-time":"2010-02-10T04:22:34Z","timestamp":1265775754000},"page":"211-214","source":"Crossref","is-referenced-by-count":0,"title":["\u00bfPodemos mejorar la prevenci\u00f3n de la tuberculosis?"],"prefix":"10.1016","volume":"28","author":[{"given":"Jos\u00e9 A.","family":"Caminero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimc.2009.12.004_bib1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1183\/09031936.04.00111204","article-title":"Controversial topics in tuberculosis. (Editorial)","volume":"24","author":"Caminero","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1016\/j.eimc.2009.12.004_bib2","first-page":"807","article-title":"Variation in vulnerability to tuberculosis in America today: random, or legacies of different ancestral epidemics?","volume":"5","author":"Stead","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib3","unstructured":"Caminero Luna JA. Gu\u00eda de la tuberculosis para m\u00e9dicos especialistas. International Union Against Tuberculosis and Lung Disease, editor. Paris, Imprimerie Chirat. Ref Type: Serial (Book,Monograph). 2003; p. 1\u2013390"},{"key":"10.1016\/j.eimc.2009.12.004_bib4","first-page":"4","article-title":"TB control: with present methods? With BCG vaccination? Or with isoniazid prophylaxis?","volume":"53","author":"Ferebee","year":"1967","journal-title":"Nat Tuberc Assoc Bull"},{"key":"10.1016\/j.eimc.2009.12.004_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0025-7753(01)71777-0","article-title":"\u00bfEs la quimioprofilaxis una buena estrategia para el control de la tuberculosis?","volume":"116","author":"Caminero Luna","year":"2001","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.eimc.2009.12.004_bib6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1164\/ajrccm.163.4.2009100","article-title":"Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells","volume":"163","author":"Lalvani","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2009.12.004_bib7","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1378\/chest.06-2471","article-title":"Diagnosing tuberculosis infection in the 21st century. New tools to tackle an old enemy","volume":"131","author":"Lalvani","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.eimc.2009.12.004_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/rccm.200509-1516PP","article-title":"An update on the diagnosis of tuberculosis infection","volume":"174","author":"Richeldi","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.eimc.2009.12.004_bib9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7326\/0003-4819-146-5-200703060-00006","article-title":"Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research","volume":"146","author":"Menzies","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2009.12.004_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1157\/13126836","article-title":"Diagn\u00f3stico y tratamiento de la tuberculosis","volume":"44","author":"Ruiz-Manzano","year":"2008","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.eimc.2009.12.004_bib11","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.12.004_bib12","first-page":"209","article-title":"Low adherence to guidelines for preventing TB among persons with newly diagnosed HIV infection, United States","volume":"10","author":"Lee","year":"2006","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib13","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1097\/00002030-199815000-00013","article-title":"Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City","volume":"12","author":"Sackoff","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2009.12.004_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1086\/510080","article-title":"Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission","volume":"44","author":"Elzi","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.157.15.1729","article-title":"Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival","volume":"157","author":"Moreno","year":"1997","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eimc.2009.12.004_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(93)91817-6","article-title":"Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection","volume":"342","author":"Pape","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2009.12.004_bib17","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/QAD.0b013e328216f441","article-title":"The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil","volume":"21","author":"Golub","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2009.12.004_bib18","first-page":"927","article-title":"Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues","volume":"13","author":"A\u00eft-Khaled","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00002030-199509030-00008","article-title":"Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre","volume":"9","author":"Aisu","year":"1995","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2009.12.004_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1164\/ajrccm\/146.1.57","article-title":"Results of a directly observed intermittent isoniazid preventive therapy program in a shelter for homeless men","volume":"146","author":"Nazar-Stewart","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib21","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? (Counterpoint)","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00002030-199903110-00009","article-title":"Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials","volume":"13","author":"Bucher","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.eimc.2009.12.004_bib23","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eimc.2009.12.004_bib24","first-page":"943","article-title":"Antituberculous chemoprophylaxis. (Correspondence)","volume":"127","author":"Zorini","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib25","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"17","author":"Ferebee","year":"1969","journal-title":"Adv Tuberc Res"},{"key":"10.1016\/j.eimc.2009.12.004_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"Hong Kong Chest Service, Tuberculosis Research Centre Madras, British Medical Research Council A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1086\/380966","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial","volume":"38","author":"Jasmer","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eimc.2009.12.004_bib28","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","article-title":"Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection","volume":"351","author":"Halsey","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.eimc.2009.12.004_bib29","first-page":"1445","article-title":"Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected patients","volume":"283","author":"Gordin","year":"2000","journal-title":"An international randomized trial. JAMA"},{"key":"10.1016\/j.eimc.2009.12.004_bib30","first-page":"1","article-title":"Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations","volume":"47","year":"1998","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.eimc.2009.12.004_bib31","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial","volume":"137","author":"Jasmer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eimc.2009.12.004_bib32","first-page":"289","article-title":"Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection-New York and Georgia, 2000","volume":"50","year":"2001","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.eimc.2009.12.004_bib33","article-title":"Inferferon gamma release assays: principles and practice","author":"Lalvani","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2009.12.004_bib34","article-title":"Factores asociados con la no realizaci\u00f3n de la prueba de la tuberculina en una cohorte de pacientes VIH positivos","author":"D\u00edaz","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.eimc.2009.12.004_bib35","article-title":"Usar rifampicina m\u00e1s pirazinamida en profilaxis antituberculosa no incrementa el riesgo de hepatotoxicidad grave en pacientes infectados por virus de la inmunodeficiencia humana: metaan\u00e1lisis de ensayos cl\u00ednicos aleatorizados y controlados","author":"Camacho","year":"2009","journal-title":"Enferm Infecc Microbiol Clin"}],"container-title":["Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X10000443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213005X10000443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T04:29:10Z","timestamp":1544675350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213005X10000443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0213005X10000443"],"URL":"https:\/\/doi.org\/10.1016\/j.eimc.2009.12.004","relation":{},"ISSN":["0213-005X"],"issn-type":[{"value":"0213-005X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}